Healthcare Global Enterprises Limited — PPTs, 04-12-2025: Investor Presentation

HCG, India's largest oncology-focused hospital chain, is redefining cancer care.

**Business Performance:** HCG delivered robust financial performance with FY25 revenue at **2,222.8 Cr** and Adjusted EBITDA at **396.3 Cr**. For Q2 FY26, revenue jumped 18% YoY to **632.1 Cr**, and H1 FY26 saw a 17% YoY rise to **1,230.3 Cr**. Patient volumes grew impressively, up 17% YoY in Q2 FY26 to 77,843 and 15% YoY in H1 FY26 to 151,074. The company has a strong track record, reducing its gross mortality rate to an industry-leading 0.9%.

**Growth Drivers or Strategy:** The company plans significant expansion, aiming to add ~1,000 beds and 8-10 LINACs over the next five years, focusing on brownfield growth and high-potential new cities. Strategies include optimizing its existing network, investing in new growth, improving efficiency, and enhancing patient experience. Efforts are also on to improve payor mix and leverage digital technology.

**Recent Developments:** HCG recently acquired centers in Indore (**45 Cr**) and Vizag (**206 Cr**), bolstering its footprint. It continues to invest in cutting-edge technology like MR-LINAC and robotics, reinforcing its position at the forefront of cancer treatment.

**Management Commentary / Outlook:** Management anticipates revenue growth to outpace the industry and historical rates, with EBITDA growth also accelerating, driven by operating leverage. The focus remains on building a future-ready organization that delivers superior patient outcomes and consistent scaling.